✦ LIBER ✦

Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with alzheimer's disease

✍ Scribed by Kent M. Perryman; L. Jaime Fitten

Book ID: 118346454
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 474 KB
Volume: 53
Category: Article
ISSN: 0024-3205
DOI: 10.1016/0024-3205(93)90699-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Melissa officinalis extract in the treat

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

✍ Akhondzadeh, S 📂 Article 📅 2003 🏛 BMJ Publishing Group 🌐 English ⚖ 224 KB

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study

✍ Vee. P. Prasher; Adam Huxley; M. S. Haque 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. ## Method This

Combined treatment with cerebrolysin and

Combined treatment with cerebrolysin and donepezil in mild to moderate alzheimer's disease: Results of a double-blind, randomized clinical trial

✍ Anton Alvarez; Ramon Cacabelos; Manuel Aleixandre; Carlos Linares; Elias Granizo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Results from CONNECTION: A global, Phase

Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease

✍ Rachelle S. Doody; Pierre Tariot; Jeff Cummings; Bengt Winblad; Bryan Selby; And 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

A placebo-controlled, double-blind trial

A placebo-controlled, double-blind trial of the selective AB-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer’s disease

✍ Gordon K. Wilcock; Sandra Black; Judy Haworth; Mark Laughlin; Suzanne Hendrix; M 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 49 KB